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Abstract Signal transduction of activin, one of the members in
the transforming growth factor-L superfamily, is initiated by
ligand binding with two distinct membrane receptors (type II and
type I) followed by activation of Smad2 or Smad3. We report
here that activin-induced signaling is negatively regulated by
another Smad molecule, Smad7. When expressed in Chinese
hamster ovary cells, Smad7 inhibited the transcriptional response
induced by either activin treatment or a constitutively active
activin type I receptor (ALK-4). In addition, Smad7 also
inhibited mouse FAST-2-mediated transactivation of the Xeno-
pus Mix.2 promoter stimulated by the constitutively active
ALK-4. Smad7 was able to directly associate with ALK-4 and
this association was dependent on the phosphorylation of the
type I receptor in its GS domain by activin type II receptors.
Expression of kinase defective activin type II receptors
decreased the association of Smad7 with ALK-4. Correspond-
ingly, Smad7 bound poorly to a mutant ALK-4 bearing serine to
alanine substitutions in four putative phosphorylation sites in its
GS domain. These studies not only illustrated the counter
regulatory function of Smad7 on activin signaling, but also
indicated the involvement of phosphorylation at activin type I
receptor in the inhibitory action of Smad7. , 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Signal transduction by transforming growth factor-L
(TGF-L) family members, including TGF-Ls, activins and
bone morphogenetic proteins (BMPs) is initiated by the inter-
action of a ligand, in the form of a dimerized peptide, with
two types (type I and type II) of transmembrane serine kinase
receptors kinases [1]. TGF-Ls and activins ¢rst interact with
their cognate type II receptors and the ligand/type II receptor
complex subsequently recruits the type I receptors into a het-
eromeric complex on the cell surface. In the heteromeric li-
gand/receptor complex, the type II receptor phosphorylates
the type I receptor within a glycine- and serine-rich GS do-
main and initiates downstream signaling. Mutations of the
putative phosphorylation sites in the GS domain of the activin
type I receptor, ALK-4, to neutral amino acids abrogates
ALK-4-mediated signaling [2,3]. On the other hand, a muta-
tion of a threonine 206 in ALK-4 or 204 in TGF-L type I
receptor (ALK-5) to an acidic amino acid generates a consti-
tutively active type I receptor that can signal in the absence of
ligand and type II receptors [3,4]. The activated type I recep-
tor is thus the transducer responsible for the propagation of
the signal to downstream targets.
The Smads comprise a family of proteins that function as
intracellular signaling mediators and modulators of the
TGF-L family members [5,6]. Functional and structural con-
siderations allow subdivision of Smads into three subfamilies:
pathway-speci¢c, common mediator and inhibitory Smads.
Pathway-speci¢c Smads are activated by type I receptor serine
kinases in a ligand and type II receptor-dependent manner.
This subfamily includes Smad1, 2, 3, 5 and 8 [6]. Smad1 and 5
mediate signaling by BMP2 and 4 [7^10], Smad2 and 3 medi-
ate signaling by TGF-L and activins [11^14], and Smad8 me-
diates signaling by the receptor serine kinase, ALK-2 [15]. The
second Smad subfamily is represented by Smad4 [16], which
serves as a common signaling mediator. Activation of the
pathway-speci¢c Smads by their individual receptors induces
an association of these Smads with Smad4 and this associa-
tion is critical for nuclear translocation and proper down-
stream signaling [17].
Smad6, Smad7 and the Drosophila DAD (daughters against
dpp) comprise the third Smad subfamily and have been re-
ported to function as negative regulators of receptor serine
kinases of TGF-L family members [18^23]. Both Smad6 and
Smad7 have been shown to inhibit signal transduction by the
TGF-L receptor, ALK-5 [18,19]. In addition, Smad7 was able
to inhibit activin signaling [24], while Smad6 was reported to
inhibit BMP signaling [20]. A Xenopus Smad7 homolog was
also reported recently to antagonize activin signaling in frog
embryo [22,23]. Another Drosophila Smad, DAD was shown
to inhibit signaling by the £y BMP2/4 ortholog, dpp, in Dro-
sophila and BMP2 or 4 in the Xenopus embryo [21]. To further
elucidate the regulation of activin signaling by Smad7, we
isolated a rat Smad7 homolog and studied its e¡ects on signal
transduction by the activin receptor complex and how phos-
phorylation is involved in the regulatory e¡ect of Smad7.
2. Materials and methods
2.1. Cell culture, cell transfection and plasmids
Chinese hamster ovary cells (CHO-K1) and human embryonic kid-
ney 293 cells (HEK293) were cultured in Dulbecco’s modi¢ed Eagle’s
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medium containing 10% fetal bovine serum (FBS). Cell transfection
was performed by the calcium phosphate method as previously de-
scribed [14]. For plasmids used here, the mouse FAST-2 has been
previously described by us [25]. The myc-tagged and Smad7 were
generated by in-frame fusion of the 5P-ends of rat Smad7 with CS2-
MT [26], that contains six repeats of the myc epitope sequence.
2.2. Cloning of a rat Smad7 homolog
Two degenerate primers were designed according to the sequence of
human Smad7 [18] and used in polymerase chain reaction (PCR) with
a cDNA reverse transcribed from mouse total brain RNA. The PCR
products were subcloned and their sequences were determined (Seque-
nase version 2, USB). Sequence comparison with human Smad7 in-
dicated that one of the PCR products represented the mouse Smad7
homolog. This mouse PCR fragment was then used to screen a rat
brain cDNA library at low stringency. Six independent clones were
isolated and all of them encoded the same rat Smad7 homolog. The
sequence of Smad7 was determined by sequencing both strands. The
full-length cDNA insert of Smad7 was subcloned into pCS2+ vector
for expression in cultured cells.
2.3. Promoter assay
For the luciferase assay, about 1U105 cells in a 6-cm dish were
transfected with 0.5 Wg each of 3TP-Lux and pCMV-L-gal, and
pcDNA3 (Invitrogen) was used to make up a total of 5 Wg DNA
for each transfection. About 36 h after transfection, the cells were
changed to a medium with 0.2% FBS and cultured for another 12 h.
In the activin treated groups, cells were treated with activin A (25 ng/
ml) during this 12 h period. The cells were then harvested and used in
luciferase and L-gal assays as described before [14].
2.4. Immunoprecipitation and immunoblotting analyses
For immunoprecipitation studies, the cell lysate was prepared in
NP-40 lysis bu¡er [17] and incubated with rabbit anti-ALK-4 poly-
clonal antibodies (V2 Wg/ml) in the presence of protein-A Sepharose
beads (Sigma). After incubation at 4‡C for 2 h, the Sepharose beads
were washed with the lysis bu¡er and the immunoprecipitate was
separated by 8% sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE). The proteins were then transferred to nitro-
cellulose membrane, blotted with 9E10 anti-myc antibody to detect
the myc-tagged proteins. The membranes were then incubated with a
secondary horseradish peroxidase-conjugated antibody (Bio-Rad),
and detected by Chemiluminescence Reagent Plus (NEN). For West-
ern blotting, the cell lysate, equivalent to about 1/30 of the amount
used for immunoprecipitation, were resolved on 8% SDS^PAGE and
detected by the mouse 9E10 anti-myc or polyclonal anti-ALK-4 anti-
bodies to examine the expression level of related proteins.
3. Results
3.1. Isolation of a rat Smad7 homolog
Recent studies have revealed a subclass of Smads that are
able to antagonize the signaling of TGF-L family members
[18^22,24]. To further investigate the molecular mechanism
of the inhibitory action of Smad7, we isolated a rat Smad7
homolog from a rat brain cDNA library by low stringency
hybridization with a PCR probe generated by degenerate
primers on the basis of the human Smad7 sequence [18]. At
the amino acid level, rat Smad7 is 98% identical to the mouse
ortholog [19], 97% to the human ortholog [18] and 80% to the
presumptive Xenopus ortholog [22,23]. Smad7 shares consid-
erable similarity to Smad6, consistent with the functional
studies showing that both Smad6 and Smad7 are able to in-
hibit TGF-L signaling [18^20].
3.2. Inhibition of activin-induced transcriptional activity by
Smad7
To determine if activin signaling is a¡ected by Smad7, we
expressed Smad7 in CHO-K1 cells and tested its e¡ect on
activin-induced 3TP-Lux activity. We found earlier that
CHO-K1 cells possess endogenous activin receptors and
were able to respond to activin treatment [27]. The 3TP-Lux
promoter is a fusion construct with multiple TPA-responsive
elements and the plasminogen activator inhibitor promoter. It
has been extensively used as a promoter element to test the
activity of TGF-L and activin signaling [28]. As shown in Fig.
1A, activin treatment of CHO-K1 cells transfected with vector
control could stimulate 3TP-Lux activity about four-fold.
However, co-transfection with Smad7 in these cells almost
completely blocked this activin-induced 3TP-Lux stimulation
(Fig. 1A), indicating that Smad7 is able to inhibit an activin-
induced transcriptional response.
The current model of TGF-L family signaling indicates that
the type I receptor is responsible for transducing the signals to
downstream targets. A constitutively active form of the activin
type I receptor ALK-4 (CA-ALK-4) bearing a threonine to
aspartic acid substitution at position 206 (T206D) has been
found to stimulate activin signaling in the absence of ligand
Fig. 1. Smad7 inhibits activin- and activin type I receptor-induced
transactivation. A: CHO-K1 cells were transfected with vector
(pcDNA3), 3TP-Lux (0.5 Wg), pCMV-L-gal (0.5 Wg) and Smad7 (2.5
Wg) as indicated. The fold change of luciferase activity normalized
by L-galactosidase activity was compared to the value of the vector-
transfected and unstimulated cells (set to 1) and shown as
meanSS.D. B: CHO-K1 cells were transfected with 3TP-Lux (0.5
Wg), pCMV-L-gal (0.5 Wg), CA-ALK-4 (1 Wg) and Smad7 (0.25, 0.75
and 2.5 Wg) as indicated. The 3TP-Lux assay was performed and
presented as in A. C: HEK293 cells were transfected with vector
(pcDNA3), AR3-lux (0.2 Wg), pCMV-L-gal (0.2 Wg), mouse FAST-2
(0.6 Wg), constitutively active ALK-4 (0.4 Wg), constitutively active
ALK-5 (0.4 Wg) and Smad7 (0.2, 1.0 and 4.0 Wg). The luciferase as-
say was performed as in A.
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stimulation [2]. To test if Smad7 also antagonizes activin type I
receptor-mediated signaling, CA-ALK-4 was used to stimulate
3TP-Lux activity in CHO-K1 cells and the e¡ect of Smad7
was studied (Fig. 1B). When the cells were transfected with
CA-ALK-4 alone, 3TP-Lux activity was increased to about
¢ve-fold as compared to the vector control. However, co-ex-
pression of Smad7 with CA-ALK-4 led to a dose-dependent
decrease of 3TP-Lux stimulation by CA-ALK-4. At the high-
est concentration, Smad7 completely blocked CA-ALK-4-in-
duced 3TP-Lux activation. These ¢ndings suggest that the
block of activin signaling by Smad7 can occur after receptor
activation.
Recent studies have suggested that a group of forkhead
transcription factors (FAST-1 in Xenopus and human,
FAST-2 in mouse) are involved in the regulation of Mix.2
and goosecoid promoters [25,29^31]. We examined if Smad7
was also able to inhibit the FAST-2-mediated transcriptional
regulation on the Xenopus Mix.2 promoter, AR3-lux, that
contains three tandem repeat of activin-responsive element
in the front of a luciferase reporter [18]. In the presence of
mouse FAST-2, both CA-ALK-4 and TGF-L type I receptor
(CA-ALK-5) was able to stimulate the AR3-lux activity to
over 40-fold (Fig. 1C). However, co-expression of Smad7
led to a dose-dependent inhibition of the active ALK-4- and
ALK-5-mediated stimulation of AR3-lux (Fig. 1C). These
data further suggest that Smad7 is able to antagonize the
signaling of activin receptor.
3.3. Association of Smad7 with ALK-4
To address the possibility that Smad7 blocks activin signal-
Fig. 2. Association of Smad7 with ALK-4. HEK293 cells were transfected with activin type IIB receptor and a myc-tagged Smad7 with di¡er-
ent forms of ALK-4 including wild-type (wt), a constitutively active T206D mutant (CA), a kinase defective mutant (KD) and a double mutant
of T206D with defective kinase (CA/KD). Cells were treated with activin (25 ng/ml) for 15 or 60 min as indicated. The transfected cells were
lysed 48 h after transfection and the ALK-4 was immunoprecipitated with a polyclonal anti-ALK-4 antibody and the immunoprecipitate was
blotted with an anti-myc antibody (upper panel). The crude cell lysate was also blotted with anti-myc and anti-ALK-4 antibodies to determine
the protein expression level of the tagged Smad7 and ALK-4 (lower panels). The possible phosphorylation state of ALK-4 is labeled as
pALK-4 for hypophosphorylated receptor and ppALK-4 for hyperphosphorylated receptor.
Fig. 3. Kinase defective activin type II receptors inhibit association
of Smad7 with ALK-4. HEK293 cells were transfected with ALK-4,
a myc-tagged Smad7 (myc/Smad7), a wild-type (wt) activin type IIB
receptor, a kinase defective (KD) activin type IIB or type II recep-
tors as indicated. The cell lysate was immunoprecipitated with an
anti-ALK-4 antibody and blotted with an anti-myc antibody (upper
panel). The crude cell lysate was also blotted with anti-myc and
anti-ALK-4 antibodies to determine the protein expression level of
Smad7 and ALK-4 (lower panels). The possible phosphorylation
state of ALK-4 is labeled as pALK-4 for hypophosphorylated re-
ceptor and ppALK-4 for hyperphosphorylated receptor.
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ing by association with the activin type I receptor, we ex-
pressed a myc-tagged Smad7 with di¡erent forms of ALK-4
in HEK293 cells and studied their possible interactions by a
co-immunoprecipitation experiment. As shown in Fig. 2,
Smad7 did interact with ALK-4 in the absence of ligand stim-
ulation when both activin type I and type II receptors were
overexpressed (lane 4). Activin treatment for 15 or 60 min in
these cells had no apparent e¡ect on the association between
Smad7 and ALK-4 (lanes 5 and 6). The Smad7/ALK-4 asso-
ciation was not dependent on the kinase activity of the type I
receptor because the kinase defective ALK-4 mutant gener-
ated by changing lysine to arginine at position 234 [27] was
also able to associate with Smad7 at a level similar to that of
wild-type ALK-4 (lane 8). Interestingly, the constitutively ac-
tive ALK-4 (T206D) mutant [2,32] showed 3^4-fold more as-
sociation with Smad7 than did the wild-type ALK-4 (lane 7).
This elevated Smad7 association also occurred to the ALK-4
double mutant that bears the T206D and the kinase defective
mutation (lane 9). We also noted that the mobility of the
T206D mutant protein was less than that of wild-type
ALK-4 in SDS^PAGE gel (lanes 7 and 9, lower panel), per-
haps due to an increase in negative charge.
3.4. Phosphorylation of ALK-4 by the activin type II receptor
regulates association with Smad7
Our observation that the T206D mutation mimicking phos-
phorylation of ALK-4 could enhance its binding to Smad7
(Fig. 2) suggests that the interaction of Smad7 with the re-
ceptor might be a¡ected by the phosphorylation state in the
GS domain of ALK-4. To address this question, we tested if
the association of ALK-4 with Smad7 is dependent on the
kinase activity of the activin type II receptors. It has been
shown that overexpression of both activin type I and type II
receptors together is able to mediate activin signaling in a
ligand independent manner [2]. This ¢nding was interpreted
to indicate that overexpression of the type II receptor is able
to force formation of a complex with the type I receptor and
activation of the type I receptor by phosphorylating its GS
domain in the absence of ligand. We co-expressed a myc-
tagged Smad7 and ALK-4 in HEK293 cells and examined
the association of Smad7 with ALK-4 in the presence of a
wild-type type II receptor or kinase defective type II receptors.
The kinase defective activin type IIB receptor was made by
mutation of lysine to arginine at position 214 [2] and the ki-
nase defective activin type II receptor was generated by mu-
Fig. 4. Association of Smad7 with ALK-4 is dependent on the phosphorylation in the GS domain by activin type II receptors. A: Schematic
representation of ALK-4 and the ALK-4 4SA mutant. The extracellular domain (ECD), transmembrane domain (TM), GS domain, serine ki-
nase domain and the position of mutations are indicated. B: Co-expression of the activin type IIB receptor does not increase association of
ALK-4 4SA with Smad7. HEK293 cells were transfected with the wild-type ALK-4 (wt), the serine to alanine mutant of ALK-4 (4SA), an acti-
vin type IIB receptor and a myc-tagged Smad7 (myc/Smad7). The cell lysate was immunoprecipitated with an anti-ALK-4 antibody and blotted
with an anti-myc antibody (upper panel). The crude cell lysate was blotted with anti-myc and anti-ALK-4 antibodies to determine the protein
expression level of Smad7 and ALK-4 (lower panels).
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tation of lysine to glutamate at position 200 [27]. As shown in
Fig. 3, ALK-4 bound strongly to Smad7 when a wild-type
activin type II receptor was co-expressed (lane 2). However,
co-expression of either a kinase defective activin type IIB
(lane 3) or a kinase defective activin type II receptor (lane 4)
could not facilitate association of ALK-4 with Smad7. From
these results, we infer that phosphorylation of the activin type
I receptor by type II receptor is required for the association of
ALK-4 with Smad7. Because it is the kinase activity of the
type II receptor that e¡ects the phosphorylation of the activin
type I receptor, the phosphorylation status of ALK-4 as well
as its ability to associate with Smad7 should not be a¡ected
by the kinase defective ALK-4 (Fig. 2, lane 8). Likewise, the
forced phosphorylation of ALK-4 by overexpressed type II
receptor may also mask the ligand-induced phosphorylation
of ALK-4 [2] and therefore results in our observation (Fig. 2,
lane 5 and 6) that activin treatment did not lead to further
increase of receptor association with Smad7.
We also noted that the phosphorylation state of ALK-4
might be re£ected by protein mobility in the immunoblotting
with the anti-ALK-4 antibody (Fig. 3, lower panel). Co-ex-
pression of the wild-type activin type IIB receptors might lead
to hyperphosphorylation of ALK-4, manifested as a slower
mobility on the gel due to its increased negative charge (Fig.
3, lane 2, lower panel). However, co-expression of the kinase
defective activin type II receptors failed to phosphorylate
ALK-4 and led to a lack of hyperphosphorylated ALK-4
with slower mobility (Fig. 3, lanes 3 and 4, lower panel).
The type II receptor-mediated ALK-4 phosphorylation has
been proposed to occur in the serine and threonine residues in
the GS domain. Mutations of these putative phosphorylation
sites into neutral amino acids can lead to loss of the down-
stream signaling [2,3]. If the association of ALK-4 with
Smad7 is dependent on the phosphorylation in the GS do-
main, we hypothesized that such mutations would abrogate
the association. Based on this consideration, we examined the
ability of one of these mutants, 4SA (Fig. 4A) to associate
with Smad7. This mutant has been reported to be functionally
de¢cient in mediating activin-induced 3TP-Lux activation [3].
As shown in Fig. 4B, wild-type ALK-4 weakly associated with
Smad7 in the absence of the activin type IIB receptor (lane 2)
and this association is greatly enhanced by co-expression of
the activin type IIB receptor (lane 3). The ALK-4 4SA mutant
was also able to weakly associate with Smad7 (lane 4) and this
modestly elevated binding was apparently due to increased
protein expression judged by the Western blotting (Fig. 4B,
the lower panel). However, co-expression of the activin type
IIB receptor did not further elevate the association of ALK-4
4SA with Smad7 (Fig. 4B, lane 5), consistent with our hypoth-
esis that the association of Smad7 with ALK-4 is dependent
upon its phosphorylation in the GS domain by the type II
receptors. The phosphorylation state of ALK-4 might also be
revealed by the change of mobility in SDS^PAGE gel (Fig. 4,
lower panel). Co-expression of activin type IIB receptors led
to an increase in the amount of hyperphosphorylated ALK-4
(lane 2, lower panel), but failed to hyperphosphorylate the
ALK-4 4SA mutant (lane 4, lower panel).
4. Discussion
We present evidence that Smad7 is able to negatively mod-
ulate signal transduction by the activin receptor serine kinase
complex. One of the molecular mechanisms underlying the
antagonization of TGF-L superfamily member signaling by
Smad7 appears to be related to the association of Smad7
with the type I receptors. Smad7 was reported to weakly
bind the wild-type TGF-L type I receptor and the association
was greatly elevated with a constitutively active TGF-L type I
receptor [18]. We found here that Smad7 can associate with
ALK-4, the type I activin receptor, and that the association of
Smad7 with a constitutively active ALK-4 mutant is stronger
than to the wild-type receptor. Our data also suggest that the
association of Smad7 with ALK-4 is regulated by the phos-
phorylation of the type I receptor in the GS domain by the
type II receptor. This is further supported by our observation
that co-expression of the activin type IIB receptor did not
further elevate the association of ALK-4 4SA mutant with
Smad7 (Fig. 4), although we could not rule out the possibility
that the 4SA mutation may change the overall structure of
ALK-4 and its a⁄nity for Smad7. Nevertheless, our results
suggest that Smad7 may interfere with signal transduction
from the type I receptor to Smad2 or Smad3 proteins by
binding to the activated type I receptor. This binding may
displace the ligand-induced transient association of the path-
way-speci¢c Smads with the receptor and block the phosphor-
ylation of these pathway-speci¢c Smads by the receptor. This
is evidenced by the ¢nding that Smad7 is able to block the
transient association of Smad2 and Smad3 with activin recep-
tor complex upon ligand stimulation [33]. Another proposed
mechanism of action for the inhibitory Smads involves a di-
rect interaction with pathway-speci¢c Smads. Smad6 was re-
ported to directly associate with Smad1 forming an inactive
complex and consequently disrupting the Smad1/Smad4 asso-
ciation induced by BMP receptor activation [34]. Such a
mechanism seems unlikely to apply to the inhibition of activin
signaling by Smad7 because we could not detect any associa-
tion of Smad7 with Smad2 by co-immunoprecipitation assay
(data not shown).
It is noteworthy that the association of Smad7 with ALK-4
is dependent on the phosphorylation in the GS domain of
ALK-4 and on the kinase activity of its corresponding type
II receptors. These observations are also consistent with the
¢ndings that the mimicked phosphorylation in the constitu-
tively active activin and TGF-L type I receptors could lead to
a stronger association with Smad7 than do the wild-type re-
ceptors. This increased association of Smad7 with activated
type I receptors may promote termination of receptor signal-
ing. Future studies of the molecular mechanisms by which the
phosphorylation of the type I receptors by the type II recep-
tors a¡ects the Smad7 binding would undoubtedly help to
elucidate the structure/function relationships of the Smad/re-
ceptor interactions. These studies may also reveal new ways to
develop therapeutic approaches to modulate the signaling by
TGF-L superfamily members.
Activin and its cognate receptor serine kinases are involved
in various biological processes including reproduction, eryth-
ropoiesis, neuronal di¡erentiation and early development [35].
Two extracellular regulators, inhibin and follistatin, have been
identi¢ed previously to antagonize the activity of activin [35].
Inhibin shares a common subunit with activin and exerts its
inhibitory e¡ect by interacting with betaglycan, a speci¢c in-
hibin receptor [36]. Follistatin inhibits activin function by
forming an inactive complex with activin [37]. Our studies
here, together with recent reports from other groups, has in-
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dicated another mode of regulation of activin function by
Smad7, which may participate in an intracellular negative
feedback pathway that serves to counter-regulate activin re-
ceptor serine kinase stimulation.
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